Orbital Therapeutics
Orbital Therapeutics is dedicated to unleashing the full potential of RNA medicines to treat human diseases in innovative ways. With a comprehensive platform that integrates established and emerging RNA technologies, delivery methods, data science, and automation, the company aims to develop an expansive portfolio of medicines. Their initial focus areas include immunomodulation for autoimmune disease and oncology, next-generation vaccines, and protein therapeutics. Led by a team of scientific pioneers and biopharma industry leaders, Orbital strives to advance the future of RNA medicines and global health.
Industries
Nr. of Employees
small (1-50)
Orbital Therapeutics
Products
Immunomodulatory RNA therapeutics (in vivo CAR and immunomodulator expression)
RNA-based programs designed to modulate the immune system by expressing CARs and other immunomodulatory proteins in vivo for autoimmune disease and oncology indications.
Next-generation mRNA vaccines
Vaccine constructs and regimens that extend beyond first-generation approaches, including heterologous prime–boost strategies, multi-antigen combinations, and polyfunctional designs combining antigen and immune enhancers.
Protein therapeutics delivered via RNA
Programs to deliver therapeutic proteins through RNA platforms, addressing expression durability, protein size and complexity, extrahepatic delivery, and redosing.
Immunomodulatory RNA therapeutics (in vivo CAR and immunomodulator expression)
RNA-based programs designed to modulate the immune system by expressing CARs and other immunomodulatory proteins in vivo for autoimmune disease and oncology indications.
Next-generation mRNA vaccines
Vaccine constructs and regimens that extend beyond first-generation approaches, including heterologous prime–boost strategies, multi-antigen combinations, and polyfunctional designs combining antigen and immune enhancers.
Protein therapeutics delivered via RNA
Programs to deliver therapeutic proteins through RNA platforms, addressing expression durability, protein size and complexity, extrahepatic delivery, and redosing.
Services
Research collaborations and technology licensing
Collaborative research agreements and licensing of RNA and non-viral delivery technologies to enable joint development of RNA medicines.
In-house platform R&D for RNA medicine discovery
Internal accelerated design–test–optimize workflows combining RNA chemistry, delivery formulation, machine learning, and protein engineering to generate therapeutic candidates.
Research collaborations and technology licensing
Collaborative research agreements and licensing of RNA and non-viral delivery technologies to enable joint development of RNA medicines.
In-house platform R&D for RNA medicine discovery
Internal accelerated design–test–optimize workflows combining RNA chemistry, delivery formulation, machine learning, and protein engineering to generate therapeutic candidates.
Expertise Areas
- RNA therapeutic design and engineering
- Delivery vehicle engineering (LNPs and VLPs)
- mRNA vaccine development
- Immunomodulatory therapeutics (in vivo expression)
Key Technologies
- Linear mRNA
- Circular RNA
- Lipid nanoparticles (LNPs)
- Virus-like particles (VLPs)